Tillar Wenstrup Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,620 shares of the company’s stock after selling 216 shares during the quarter. Johnson & Johnson comprises 1.8% of Tillar Wenstrup Advisors LLC’s portfolio, making the stock its 25th largest position. Tillar Wenstrup Advisors LLC’s holdings in Johnson & Johnson were worth $2,331,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Lenox Wealth Advisors Inc. raised its stake in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares in the last quarter. Lbmc Investment Advisors LLC raised its stake in Johnson & Johnson by 0.4% during the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after buying an additional 14 shares in the last quarter. Stratford Consulting LLC raised its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Stratford Consulting LLC now owns 2,728 shares of the company’s stock worth $361,000 after purchasing an additional 16 shares during the period. Iron Financial LLC raised its position in shares of Johnson & Johnson by 0.5% during the 2nd quarter. Iron Financial LLC now owns 3,782 shares of the company’s stock worth $500,000 after purchasing an additional 19 shares during the period. Finally, North Point Portfolio Managers Corp OH raised its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. North Point Portfolio Managers Corp OH now owns 2,923 shares of the company’s stock worth $387,000 after purchasing an additional 20 shares during the period. Hedge funds and other institutional investors own 65.93% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Tillar Wenstrup Advisors LLC Cuts Holdings in Johnson & Johnson (JNJ)” was originally published by Stock Observer and is owned by of Stock Observer. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.thestockobserver.com/2017/11/15/tillar-wenstrup-advisors-llc-cuts-holdings-in-johnson-johnson-jnj.html.
Johnson & Johnson (NYSE:JNJ) opened at $139.49 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The stock has a market capitalization of $375,468.03, a price-to-earnings ratio of 19.57, a price-to-earnings-growth ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a one year low of $109.32 and a one year high of $144.35.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $1.68 EPS. equities research analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.41%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
JNJ has been the topic of a number of research reports. UBS AG reiterated a “buy” rating and set a $148.00 price target (up from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) cut Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their price target for the stock from $125.00 to $130.00 in a research report on Wednesday, September 20th. BMO Capital Markets reiterated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Friday, September 1st. Alembic Global Advisors cut Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Finally, Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $143.70.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.